Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.404 FI de cinco anos: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v27.i5.10
pages 401-414

PART IV. Cytokine and Hormone Immunotherapy
Treatment of AIDS-Related Kaposi's Sarcoma with Interleukin-12: Rationale and Preliminary Evidence of Clinical Activity

Robert Yarchoan
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1868, USA
James M. Pluda
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1868, USA
Kathleen M. Wyvill
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1868, USA
Karen Aleman
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1868, USA
Isaac R. Rodriguez-Chavez
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1868, USA
Giovanna Tosato
Laboratory of Cellular Oncology; Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1868, USA
Andrew T. Catanzaro
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1868, USA
Seth M. Steinberg
Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1868, USA
Richard F. Little
HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1868, USA

RESUMO

In this article, we review the preliminary evidence for the activity of interleukin-12 (IL−12) against Kaposi's sarcoma (KS) and discuss these results in the context of the biology of IL−12 and KS. IL−12 is a cytokine that enhances type 1 immunity, induces production of interferon gamma (IFN−γ), and mediates antiangiogenic effects. In addition, it can downregulate a constitutively active G protein coupled receptor that is encoded by Kaposi's sarcoma−associated herpesvirus, the causative agent of KS. These factors suggested that IL−12 might be worth exploring as a potential anti−KS agent. In an initial phase I pilot study, IL−12 was found to have anti−KS activity when used alone in patients with AIDS−associated KS who were on a stable regimen of antiretroviral therapy. In preliminary results from a subsequent study of the combination of IL−12 plus liposomal doxorubicin along with highly active antiretroviral therapy, remissions were obtained in a substantial percentage of patients with advanced AIDS−associated KS. IL−12 has also been found active in patients with certain lymphomas. These results suggest that IL−12 may be worth exploring further as a potential antitumor agent in selected tumors.


Articles with similar content:

PART V. Modulation of Antitumor Vaccine Strategies
Preclinical and Clinical Studies of Recombinant Poxvirus Vaccines for Carcinoma Therapy

Critical Reviews™ in Immunology, Vol.27, 2007, issue 5
Philip M. Arlen, Jeffrey Schlom, Ravi A. Madan, James L. Gulley, James W. Hodge
Checkpoint Modulators in Cancer Immunotherapy
Onco Therapeutics, Vol.5, 2014, issue 1-2
Jean Sathish
The Medicinal Benefits of Lentinan (β-1, 3-D glucan) from Lentinus edodes (Berk.) Singer (Shiitake Mushroom) Through Oral Administration
International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 1&2
Mah-Lee Ng, Ann-Teck Yap
Paradoxical Role of Dengue Virus Envelope Protein Domain III Antibodies in Dengue Virus Infection
Critical Reviews™ in Eukaryotic Gene Expression, Vol.30, 2020, issue 3
Muhammad Shahid, Muhammad Idrees, Sheeza Ali, Ayma Aftab, Muhammad Zubair Yousaf, Samia Afzal, Iram Amin
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Mark C. Kelley